Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies

Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies

Abstract Introduction Proteinuria is a modifiable risk factor for chronic kidney disease (CKD) progression in children. Finerenone, a selective, non-steroidal, mineralocorticoid receptor antagonist (MRA) has been approved to treat adults with CKD associated with type 2 diabetes mellitus (T2DM) follo...

Full description

Bibliographic Details
Main Authors: Franz Schaefer, Giovanni Montini, Hee Gyung Kang, Johan Vande Walle, Joshua Zaritsky, Michiel F. Schreuder, Mieczyslaw Litwin, Andrea Scalise, Helen Scott, James Potts, Pablo Iveli, Stefanie Breitenstein, Bradley A. Warady
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Trials
Subjects:
Chronic kidney disease
Finerenone
Mineralocorticoid
Pediatric
Proteinuria
Renoprotective therapy
Online Access:https://doi.org/10.1186/s13063-024-08021-z

Internet

https://doi.org/10.1186/s13063-024-08021-z

Similar Items